Year |
Citation |
Score |
2017 |
Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS, Miller MA, Carlson JC, Freeman GJ, Anthony RM, Weissleder R, Pittet MJ. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Science Translational Medicine. 9. PMID 28490665 DOI: 10.1126/Scitranslmed.Aal3604 |
0.337 |
|
2016 |
Giedt RJ, Fumene Feruglio P, Pathania D, Yang KS, Kilcoyne A, Vinegoni C, Mitchison TJ, Weissleder R. Computational imaging reveals mitochondrial morphology as a biomarker of cancer phenotype and drug response. Scientific Reports. 6: 32985. PMID 27609668 DOI: 10.1038/Srep32985 |
0.306 |
|
2016 |
Giedt RJ, Fergulio PF, Pathania D, Yang KS, Kilcoyne A, Vinegoni C, Mitchison TJ, Weissleder R. Abstract 234: Mitochondrial morphology as a biomarker of cancer phenotype and drug response Cancer Research. 76: 234-234. DOI: 10.1158/1538-7445.Am2016-234 |
0.3 |
|
2015 |
Miller MA, Zheng YR, Gadde S, Pfirschke C, Zope H, Engblom C, Kohler RH, Iwamoto Y, Yang KS, Askevold B, Kolishetti N, Pittet M, Lippard SJ, Farokhzad OC, Weissleder R. Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug. Nature Communications. 6: 8692. PMID 26503691 DOI: 10.1038/Ncomms9692 |
0.328 |
|
2015 |
Kim E, Yang KS, Kohler RH, Dubach JM, Mikula H, Weissleder R. Optimized Near-IR Fluorescent Agents for in Vivo Imaging of Btk Expression. Bioconjugate Chemistry. PMID 26017814 DOI: 10.1021/Acs.Bioconjchem.5B00152 |
0.366 |
|
2015 |
Yang KS, Kohler RH, Landon M, Giedt R, Weissleder R. Single cell resolution in vivo imaging of DNA damage following PARP inhibition. Scientific Reports. 5: 10129. PMID 25984718 DOI: 10.1038/Srep10129 |
0.322 |
|
2014 |
Laughney AM, Kim E, Sprachman MM, Miller MA, Kohler RH, Yang KS, Orth JD, Mitchison TJ, Weissleder R. Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin. Science Translational Medicine. 6: 261ra152. PMID 25378644 DOI: 10.1126/Scitranslmed.3009318 |
0.33 |
|
2014 |
Giedt RJ, Sprachman MM, Yang KS, Weissleder R. Imaging cellular distribution of Bcl inhibitors using small molecule drug conjugates. Bioconjugate Chemistry. 25: 2081-5. PMID 25333750 DOI: 10.1021/Bc500433K |
0.36 |
|
2014 |
Kim E, Yang KS, Giedt RJ, Weissleder R. Red Si-rhodamine drug conjugates enable imaging in GFP cells. Chemical Communications (Cambridge, England). 50: 4504-7. PMID 24663433 DOI: 10.1039/C4Cc00144C |
0.313 |
|
2014 |
Thurber GM, Reiner T, Yang KS, Kohler RH, Weissleder R. Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors. Molecular Cancer Therapeutics. 13: 986-95. PMID 24552776 DOI: 10.1158/1535-7163.Mct-13-0801 |
0.341 |
|
2014 |
Miller MA, Askevold B, Yang KS, Kohler RH, Weissleder R. Platinum compounds for high-resolution in vivo cancer imaging. Chemmedchem. 9: 1131-5. PMID 24504646 DOI: 10.1002/Cmdc.201300502 |
0.319 |
|
2013 |
Kim E, Yang KS, Weissleder R. Bioorthogonal small molecule imaging agents allow single-cell imaging of MET. Plos One. 8: e81275. PMID 24265843 DOI: 10.1371/Journal.Pone.0081275 |
0.438 |
|
2013 |
Yang KS, Budin G, Tassa C, Kister O, Weissleder R. Bioorthogonal approach to identify unsuspected drug targets in live cells. Angewandte Chemie (International Ed. in English). 52: 10593-7. PMID 23960025 DOI: 10.1002/Anie.201304096 |
0.354 |
|
2013 |
Thurber GM, Yang KS, Reiner T, Kohler RH, Sorger P, Mitchison T, Weissleder R. Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. Nature Communications. 4: 1504. PMID 23422672 DOI: 10.1038/Ncomms2506 |
0.38 |
|
2012 |
Yang KS, Budin G, Reiner T, Vinegoni C, Weissleder R. Bioorthogonal imaging of aurora kinase A in live cells. Angewandte Chemie (International Ed. in English). 51: 6598-603. PMID 22644700 DOI: 10.1002/Anie.201200994 |
0.338 |
|
2012 |
Reiner T, Lacy J, Keliher EJ, Yang KS, Ullal A, Kohler RH, Vinegoni C, Weissleder R. Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents. Neoplasia (New York, N.Y.). 14: 169-77. PMID 22496617 DOI: 10.1593/Neo.12414 |
0.333 |
|
2012 |
Ullal AV, Reiner T, Yang KS, Gorbatov R, Min C, Issadore D, Lee H, Weissleder R. Abstract 1968: Nanoparticle mediated measurement of target-drug binding in cancer cells Cancer Research. 72: 1968-1968. DOI: 10.1158/1538-7445.Am2012-1968 |
0.367 |
|
2011 |
Adak S, Yang KS, Macdonald-Obermann J, Pike LJ. The membrane-proximal intracellular domain of the epidermal growth factor receptor underlies negative cooperativity in ligand binding. The Journal of Biological Chemistry. 286: 45146-55. PMID 22069315 DOI: 10.1074/Jbc.M111.274175 |
0.594 |
|
2011 |
Ullal AV, Reiner T, Yang KS, Gorbatov R, Min C, Issadore D, Lee H, Weissleder R. Nanoparticle-mediated measurement of target-drug binding in cancer cells. Acs Nano. 5: 9216-24. PMID 21962084 DOI: 10.1021/Nn203450P |
0.351 |
|
2011 |
Budin G, Yang KS, Reiner T, Weissleder R. Bioorthogonal probes for polo-like kinase 1 imaging and quantification. Angewandte Chemie (International Ed. in English). 50: 9378-81. PMID 21948435 DOI: 10.1002/Anie.201103273 |
0.363 |
|
2010 |
Yang KS, Macdonald-Obermann JL, Piwnica-Worms D, Pike LJ. Asp-960/Glu-961 controls the movement of the C-terminal tail of the epidermal growth factor receptor to regulate asymmetric dimer formation. The Journal of Biological Chemistry. 285: 24014-22. PMID 20507979 DOI: 10.1074/Jbc.M110.103317 |
0.617 |
|
2010 |
Yang RY, Yang KS, Pike LJ, Marshall GR. Targeting the dimerization of epidermal growth factor receptors with small-molecule inhibitors. Chemical Biology & Drug Design. 76: 1-9. PMID 20456371 DOI: 10.1111/J.1747-0285.2010.00986.X |
0.624 |
|
2009 |
Yang KS, Ilagan MX, Piwnica-Worms D, Pike LJ. Luciferase fragment complementation imaging of conformational changes in the epidermal growth factor receptor. The Journal of Biological Chemistry. 284: 7474-82. PMID 19171934 DOI: 10.1074/Jbc.M808041200 |
0.621 |
|
Show low-probability matches. |